Abstract 1338P
Background
Clinical research leverages cancer patient care outcomes. We analyzed the direct impact of clinical trials (CTs) in terms of clinical outcomes and costs related expenses in patients with metastatic renal cell carcinoma (mRCC) and G1-G2 neuroendocrine tumors (mNETs) in the real-life setting.
Methods
Retrospectively, clinical data of the patients related to their baseline characteristics and the efficacy of the different lines of treatment were collected, as well as the direct healthcare costs of all patients diagnosed with mRCC or mNET and clinically followed by the Ramón y Cajal University Hospital Medical Oncology Service, in Madrid, Spain, between Jan 2010-Feb 2017. Subsequently, a comparative statistical analysis was performed of the results obtained in patients included in a CT vs. standard of care (SOC) patients.
Results
Of the 104 patients (65 mRCC and 39 mNET) included, 39 participated in a CT. Overall, the CT patients presented a higher overall survival (OS) than SOC patients (52 vs. 15 months. HR: 0.41; 95% CI: [0.23; 0.71]; p < 0.01). This survival improvement was consistent through all subgroups analyzed, including age, sex and prognostic factors. Regarding healthcare costs, patients who participated in CT yielded a mean annual savings of €46,109.56 per patient (p < 0.01) compared to patients treated according to SOC, mainly due to pharmacological savings (€27,406.42). Furthermore, the savings were identified in all subgroups regardless of age, sex and prognostic factors. Additionally, CT patients required 75.81% fewer hospitalisations (p < 0.01) with a lower associated mean cost (p = 0.02), and the mean annual cost corresponding to the use of the Emergency Service was also lower (p < 0.01). Finally, the unadjusted incremental cost-effectiveness ratio (ICER) was -€14,970.64 per year of life gained (YLG) and the adjusted ICER was -€42,656.11 per life saved.
Conclusions
The participation of patients with mRCC and NET in CTs is related to an improvement in OS and cost- savings. In short, the participation of cancer patients in CTs represents a cost-efficient therapeutic option for the national health system.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
P. Gajate Borau: Financial Interests, Institutional, Advisory Board: Bayer, Roche, Ipsen, Janssen, Eisai, Sanofi, Pfizer, Merk, MSD, Adacap, Astellas; Financial Interests, Institutional, Invited Speaker: Pfizer, BMS, Roche, Novartis, Janssen, Eisai, MSD, Ipsen, Adacap; Financial Interests, Institutional, Other, Travel expenses: Ipsen, Pfizer, Sanofi, Astellas, Janssen, Roche. T. Alonso Gordoa: Financial Interests, Personal, Advisory Board: Ipsen, Sanofi, Bayer, Eisai, Novartis Advanced Accelerator Applications, Lilly; Financial Interests, Personal, Invited Speaker: Pfizer, Roche, Janssen-Cilag; Financial Interests, Institutional, Advisory Board: Bristol Myers Squibb; Non-Financial Interests, , Project Lead: Pfizer, Ipsen. J. Molina Cerrillo: Financial Interests, Personal, Advisory Board: Ipsen, Janssen, BMS, Eisai; Financial Interests, Personal, Invited Speaker: Pfizer, AAA, Roche, Janssen; Financial Interests, Personal, Expert Testimony: Astellas; Financial Interests, Personal, Research Grant: Ipsen, Pfizer. A. Carrato Mena: Financial Interests, Institutional, Advisory Board: Merk, Roche, MSD, Pfizer, Bayer, Servier, Celgene, Amgen, Baxter; Financial Interests, Institutional, Research Grant: Celgene, Amgen, BMS. E. Grande Pulido: Financial Interests, Personal, Invited Speaker: Adacap, AstraZeneca, Bristol Myers Squibb, Eisai, Eusa Pharma, IPSEN, Janssen, Lilly, Merck KGa, Pfizer, Roche; Financial Interests, Personal, Advisory Board: Astellas, Bayer, MSD, Novartis, Sanofi-Genzyme; Financial Interests, Institutional, Advisory Board: Caris Life Sciences, ONCODNA (Biosequence); Financial Interests, Institutional, Research Grant, Independent research grant: Astellas, AstraZeneca, Lexicon, MTEM/Threshold, Nanostring Technologies, Pfizer, Roche, Merck; Financial Interests, Institutional, Invited Speaker, Independent research grant: Ipsen; Non-Financial Interests, , Other, AD board member: ENETS. All other authors have declared no conflicts of interest.